Evidence map›Paper›PMID 36483200›Full record

ArticleFrontiers in microbiology2022

Therapeutic efficacy of

Ahmed Orabi, Ashraf Hussein, Ayman A Saleh, Ayman M Megahed, Mohamed Metwally, Hassan Moeini, Aya Sh Metwally

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in microbiology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.7field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Ahmed OrabiDepartment of Virology, Faculty of Veterinary Medicine, Zagazig University, Zagazig, Egypt.
Ashraf HusseinDepartment of Avian and Rabbit Medicine, Faculty of Veterinary Medicine, Zagazig University, Zagazig, Egypt.
Ayman A SalehDepartment of Animal Wealth Development, Genetics and Genetic Engineering, Faculty of Veterinary Medicine, Zagazig University, Zagazig, Egypt.
Ayman M MegahedDepartment of Veterinary Public Health, Faculty of Veterinary Medicine, Zagazig University, Zagazig, Egypt.
Mohamed MetwallyDepartment of Pathology, Faculty of Veterinary Medicine, Zagazig University, Zagazig, Egypt.
Hassan MoeiniInstitute of Virology, School of Medicine, Techenical University of Munich, Munich, Germany.
Aya Sh MetwallyDepartment of Pharmacology, Factulty of Veterinary Medicine, Aswan University, Aswan, Egypt.
Zagazig University · EGAswan University · EG

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: The control of Newcastle disease virus (NDV) infection depends solely on vaccination which in most cases is not sufficient to restrain the consequences of such a highly evolving viral disease. Finding out substances for preparing an efficient anti-ND drug would be of high value. Methods: Chickens infected with a highly virulent NDV were treated with low to high concentrations of Results: Symptoms development was found to discontinue 24-72 hours post-treatment. Survival rate in the NDV-infected chickens raised 37.4-53.2% after the treatment. Conclusion: Our findings suggest

Indexed as

domestic chickensNDn-Docosanoltherapyvirus loadvirus shedding

Identifiers

PMID36483200
PMCPMC9724783
OpenAlexW4309779837

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.